Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. - Wikidata - wikimedia - TriplyDB

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.

http://www.wikidata.org/entity/Q30405398

about

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing Genetic study of congenital bile-duct dilatation identifies de novo and inherited variants in functionally related genes Biliary tract cancers: SEOM clinical guidelines Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.New Horizons for Precision Medicine in Biliary Tract Cancers.Emerging molecular targets and therapy for cholangiocarcinoma.Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma.Emerging molecular therapeutic targets for cholangiocarcinoma.Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.Cholangiocarcinoma - evolving concepts and therapeutic strategies.Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis.Wild-type and mutated IDH1/2 enzymes and therapy responses.Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma.Targeting cholangiocarcinoma.Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas.Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis.Emerging role of precision medicine in biliary tract cancers

P2860

Q26751224-DA2D89B1-9D13-48C4-B4AA-C7409E06C56C Q26751655-72A7A0BD-56F3-4278-8D7E-F98277662A33 Q26852049-10AE837E-15F1-4260-B56D-6802FB4BEF37 Q35215602-16AC9A36-8EA5-4CB4-8AC3-3B76324D1BB5 Q36064917-7F80FB6F-19D0-466B-9424-4D4B96511B55 Q36113790-A46A8B0E-B575-4F16-961D-F7D684C3A791 Q36220868-494BC701-E5BE-4715-97BB-69D0825C4765 Q36400234-782B3483-1E31-4BC1-9E70-B1A72E10FB04 Q36884411-702AC6B1-FBD3-48BF-A654-58D3C34A7584 Q37525324-64CF5F13-9CF2-4A6C-8E96-1DA0EA371C46 Q37639577-5AAC0D74-76B6-49FF-B663-79403FB8E611 Q38466472-B833E27A-DCC7-41FE-9564-C670AD289D86 Q38619219-113B0B2A-A593-4760-BA4E-4F92167A0C1D Q38642455-34A0F4FD-78C0-4E58-A18C-94DE09210DF4 Q39022105-B7335A2C-CF2A-4E2D-834C-316F9AD3B97F Q39227356-ED1AD75C-E35B-4883-9BE3-CF13C7C29E13 Q40633762-D3A69636-7258-4BDC-9BA8-40E3F918E747 Q46087686-7F315F14-C134-4CB2-9E8F-A6CB6B6852DE Q47550861-C7F95D83-3094-4FCF-8BB6-12089365ACEC Q47713415-3C1EC7AF-EEEA-427D-9A09-A40ED9EAC850 Q50127508-930B62B2-096F-4614-9D12-786B78ECABD7 Q50947280-F5EAF398-C0A6-4E07-9B42-53AF98EF02CA Q52757760-F3D6C729-2F22-45ED-AC3B-5608EE1B40EE Q53224958-A25FBC0D-D8A9-4835-8362-D0A0482334F9 Q53710725-5336693A-C07D-4564-BCAD-D594EA09A3E9 Q55260649-3349FB96-9E77-44F1-B3B6-F4E45D29FA3F Q55307435-D650A030-364D-4F05-BC6F-C97C2D0B86A9 Q57298169-14DA5205-C66B-4EA0-BBC5-1BB22A40280B

P2860

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.

http://www.wikidata.org/entity/Q30405398

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Genomic profiling of intrahepa ...... entifying therapeutic targets.

@ast

Genomic profiling of intrahepa ...... entifying therapeutic targets.

@en

type

label

Genomic profiling of intrahepa ...... entifying therapeutic targets.

@ast

Genomic profiling of intrahepa ...... entifying therapeutic targets.

@en

prefLabel

Genomic profiling of intrahepa ...... entifying therapeutic targets.

@ast

Genomic profiling of intrahepa ...... entifying therapeutic targets.

@en

P1433

Q30405398-2EA631B5-1ACE-432F-8CA9-8B03FC33D764

P1476

Q30405398-1ED4904D-E6E8-4AC4-9D4B-F1690BF23E21

P2093

Q30405398-10DB8858-3063-44C9-8BC1-2296FFAEAEFC

Q30405398-18F04E6B-FDA0-4EA3-A9A9-B366615F7934

Q30405398-21479BC6-E08B-4B74-9A33-3ECF47CD6DD0

Q30405398-2CD60F23-D545-45DE-89A9-0978D7EF1DE4

Q30405398-33B35F21-56FB-46C4-83C3-7C196894D1EC

Q30405398-6A6ECCC3-35D9-406F-BE71-BC475903252E

Q30405398-7839F338-2465-4176-BBCB-BA06CF17D087

Q30405398-7F73A76C-CA73-4A51-96E9-67CB045B80CC

Q30405398-8902727B-49D4-4834-9EB1-C5871C630F2B

Q30405398-8DD3E94C-13C7-4386-8BA7-4EFDB942188C

P2860

Q30405398-006CB21A-E81A-4C1D-BE3B-38F3E9238389

Q30405398-06E8962F-AA51-40F1-849B-212138576FE5

Q30405398-1F6367E8-7180-4AD3-8538-724F7FD0F558

Q30405398-23FC5DD6-04D5-47A7-82FC-5883BF940235

Q30405398-25743872-C4E7-4BC5-81C2-7D5FC6B80297

Q30405398-2B9C95EF-0B85-4500-A3EF-8372925ABC1A

Q30405398-2EC4EE7F-ACC6-40CF-8BAE-EB5CE860F969

Q30405398-2F805ED9-E9AD-45B7-8182-4EB714361887

Q30405398-30747830-A1AB-4999-A69B-FAE49781F440

Q30405398-439D531A-4ACA-4F26-B72D-7E7E95FEA93C

P2888

Q30405398-A2E98FF0-09A0-4C6F-9682-5497DBCBE1CA

P304

Q30405398-FC3B9B6A-5669-4A2E-AF67-CC95B9CB50FB

P31

Q30405398-69C7E171-8CA8-4A54-9722-9E9C038FFE2D

P356

Q30405398-0EA34EDD-4CC0-469C-ADF5-7A609BF47492

P433

Q30405398-C4452EF2-9966-47B2-A431-0F6F628ED32A

P478

Q30405398-87D3FEB4-DA9E-4399-949C-48F4FE65E5D1

P50

Q30405398-0F1E3A2E-7944-462F-B1F3-AFDAA132C751

Q30405398-3D6B87FE-56A9-46DD-8D60-9FBF96E1ADC1

Q30405398-9CBB0987-F751-40B7-8F26-C2B613D61C03

Q30405398-A9FF895F-54F8-40A1-8D5D-681E160C1649

P577

Q30405398-A278F000-F756-4FDE-87FE-0E4A132EB0BB

P5875

Q30405398-F8AD1113-F273-4DF3-AFAD-729AE0A3D49B

P6179

Q30405398-59FC7EFE-47E7-488A-A2FB-CB365F1E56A0

P698

Q30405398-5B1AB636-ECA4-4A1A-8766-F6C34586A282

P921

Q30405398-5E90CC61-E486-4958-9F7F-A1F9319A4851

P932

Q30405398-25BA05DD-ADBA-4FAB-85F1-81C14E425427

P356

S10434-014-3828-X

P1433

Annals of Surgical Oncology

P1476

Genomic profiling of intrahepa ...... entifying therapeutic targets.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Cristina Ferrone

http://www.w3.org/2001/XMLSchema#string

Darrell R Borger

http://www.w3.org/2001/XMLSchema#string

David Cosgrove

http://www.w3.org/2001/XMLSchema#string

Irinel Popescu

http://www.w3.org/2001/XMLSchema#string

James M Lindberg

http://www.w3.org/2001/XMLSchema#string

Jean Francois Gigot

http://www.w3.org/2001/XMLSchema#string

Robert A Anders

http://www.w3.org/2001/XMLSchema#string

Ronnie Poon

http://www.w3.org/2001/XMLSchema#string

Ryan Thomas Groeschl

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

Genetic profiling of intrahepatic cholangiocarcinoma

Identification of targetable FGFR gene fusions in diverse cancers.

Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

P2888

s10434-014-3828-x

P304

3827-3834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-014-3828-X

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Christine Sempoux

P577

2014-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262813990

http://www.w3.org/2001/XMLSchema#string

P6179

1014604581

http://www.w3.org/2001/XMLSchema#string

P698

24889489

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

4324507

http://www.w3.org/2001/XMLSchema#string